NMD Pharma A/S: Financial statements 2018
CVR: 36899069
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
NMD Pharma A/S (CVR 36899069) has filed annual accounts for 2018. In 2018, the company reported a gross profit of EUR -4,661,848 and a net result of EUR -5,542,829 compared with DKK -21,883,435 the year before. Equity in the 2018 report amounted to EUR 87,546. The company had 14 employees in the financial year.
- Gross Profit
- EUR -4,661,848
- Profit/Loss
- EUR -5,542,829
- Equity
- EUR 87,546
- Employees
- 14
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -4.7 mio. EUR | -5.5 mio. EUR | 88 t. EUR | 14 |
| 2017 | - | -17.9 mio. | -21.9 mio. | -8.7 mio. | 13 |
| 2016 | - | -6.4 mio. | -6.9 mio. | 13.1 mio. | 5 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of December 21, 2018, EY Godkendt Revisionspartnerselskab has been appointed auditor of NMD Pharma A/S.
As of December 21, 2018, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of NMD Pharma A/S.
As of November 19, 2018, Paul Brian Little has joined the board of directors of NMD Pharma A/S.
NMD Pharma A/S has published its annual report for 2017. Gross profit came to DKK -17,857,762, and the net result was DKK -21,883,435.
As of March 5, 2018, Lucas Antoine de Breed has joined the board of directors of NMD Pharma A/S.
As of March 5, 2018, Anja Ulrike DR Harmeier has joined the board of directors of NMD Pharma A/S.
As of March 5, 2018, Claus Elsborg Olesen has left the board of directors of NMD Pharma A/S.
On March 5, 2018, the company changed its name from NMD Pharma ApS to NMD Pharma A/S.
About NMD Pharma A/S
NMD Pharma A/S is a Danish company of the type Aktieselskab based in Aarhus N, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NMD Pharma ApS. The management consists of Thomas Holm Pedersen. The board consists of Michael Thomas Heffernan (chair), Anja Ulrike Harmeier, Christian Ellebæk Elling and Ivan Andreevich Burkov. The company's owners include LUNDBECKFOND INVEST A/S, Novo Holdings A/S and Roche Finance Ltd.. The company has 64 employees (2026). In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475.